Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -18.82% | 2.67% | -20.45% | -13.99% | 8.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.82% | 2.67% | -20.45% | -13.99% | 8.99% |
| Cost of Revenue | -8.68% | -5.84% | -19.09% | -28.51% | -12.98% |
| Gross Profit | -19.20% | 3.08% | -20.51% | -13.44% | 10.03% |
| SG&A Expenses | -0.90% | -15.83% | 16.16% | -9.50% | 9.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.58% | -15.86% | 10.26% | -9.82% | 4.57% |
| Operating Income | -71.84% | 112.78% | -66.84% | -34.42% | 21.11% |
| Income Before Tax | -62.86% | 100.77% | -64.87% | 3.09% | 99.03% |
| Income Tax Expenses | -64.61% | -70.96% | -70.80% | -28.17% | 23.95% |
| Earnings from Continuing Operations | -62.42% | 100.56% | -61.97% | 20.37% | 135.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 56.89% | -2,203.45% | 50.99% | 47.31% | -21.79% |
| Net Income | -64.18% | 99.90% | -71.73% | 90.39% | 235.65% |
| EBIT | -71.84% | 112.78% | -66.84% | -34.42% | 21.11% |
| EBITDA | -66.91% | 123.23% | -63.85% | -33.86% | 22.10% |
| EPS Basic | -65.52% | 99.91% | -79.04% | 41.92% | 156.37% |
| Normalized Basic EPS | -66.82% | 97.81% | -85.74% | 19.71% | 111.76% |
| EPS Diluted | -86.39% | 99.76% | -73.80% | -70.50% | 5.33% |
| Normalized Diluted EPS | -65.40% | 97.81% | -85.21% | 21.72% | 112.96% |
| Average Basic Shares Outstanding | 3.79% | 18.45% | 34.68% | 34.46% | 30.95% |
| Average Diluted Shares Outstanding | -0.61% | 18.45% | 30.08% | 32.22% | 30.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |